CGRP-alpha responsiveness of adult rat ventricular cardiomyocytes from normotensive and spontaneously hypertensive rats

Eur J Cell Biol. 2009 Apr;88(4):227-41. doi: 10.1016/j.ejcb.2008.11.001. Epub 2009 Jan 6.

Abstract

Calcitonin gene-related peptide (CGRP)-alpha is expressed in heart ventricles in sensory nerves and cardiomyocytes. It modifies inotropism and induces ischaemic preconditioning. This study investigates the effect of CGRP-alpha on the contractile responsiveness of isolated adult ventricular rat cardiomyocytes and the effect of chronic hypertension on this interaction. Cardiomyocytes were isolated and paced at 0.5-2.0 Hz. Cell shortening was recorded via a line camera with a reading frame of 500 Hz. CGRP-alpha exerted a dual effect on cardiomyocytes with a positive contractile effect at 10nM and a negative contractile effect at 10 pM. CGRP-alpha(8-37), a calcitonin receptor-like receptor (CRLR) antagonist, attenuated the positive contractile effect. H89, a protein kinase A antagonist, converted the positive contractile effect into a negative contractile effect. The negative contractile effect was converted again back to a positive contractile effect in the presence of l-nitro arginine. In cardiomyocytes isolated from spontaneously hypertensive rats (SHR) the mRNA expression of CRLR and the receptor-associated modifier protein (RAMP)-2 were lower. However, on the protein level CLRL was up-regulated, RAMP2 expression remained unchanged, and eNOS expression was down-regulated in these cells. These cells responded with a pure positive contractile response. In Langendorff preparations, CGRP-alpha slightly reduced the rate pressure product in hearts from normotensive rats but it caused an increase in hearts from SHR. In conclusion, it is shown that CGRP-alpha exerts dual effects on cardiomyocytes favouring the negative contractile effect at very low concentrations. This effect is compensated in chronic pressure-overloaded hearts and converted into a positive inotropism.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood Pressure / physiology
  • Calcitonin Gene-Related Peptide / antagonists & inhibitors
  • Calcitonin Gene-Related Peptide / metabolism
  • Calcitonin Gene-Related Peptide / pharmacology*
  • Calcitonin Receptor-Like Protein
  • Calcium / metabolism
  • Cyclic AMP-Dependent Protein Kinases / metabolism
  • Heart Ventricles / cytology
  • Heart Ventricles / drug effects*
  • Heart Ventricles / metabolism
  • In Vitro Techniques
  • Intracellular Signaling Peptides and Proteins / metabolism
  • Isoquinolines / pharmacology
  • Membrane Proteins / metabolism
  • Myocardial Contraction / drug effects*
  • Myocardial Contraction / physiology
  • Myocytes, Cardiac / drug effects*
  • Myocytes, Cardiac / metabolism
  • Myocytes, Cardiac / physiology
  • Nitric Oxide Synthase Type III / metabolism
  • Peptide Fragments / pharmacology
  • Protein Kinase Inhibitors / pharmacology
  • Rats
  • Rats, Inbred SHR
  • Rats, Wistar
  • Receptor Activity-Modifying Protein 2
  • Receptor Activity-Modifying Proteins
  • Receptors, Calcitonin / antagonists & inhibitors
  • Sulfonamides / pharmacology
  • Ventricular Function / drug effects*
  • Ventricular Function / physiology

Substances

  • Calcitonin Receptor-Like Protein
  • Calcrl protein, rat
  • Intracellular Signaling Peptides and Proteins
  • Isoquinolines
  • Membrane Proteins
  • Peptide Fragments
  • Protein Kinase Inhibitors
  • Ramp2 protein, rat
  • Receptor Activity-Modifying Protein 2
  • Receptor Activity-Modifying Proteins
  • Receptors, Calcitonin
  • Sulfonamides
  • calcitonin gene-related peptide (8-37)
  • Nitric Oxide Synthase Type III
  • Nos3 protein, rat
  • Cyclic AMP-Dependent Protein Kinases
  • Calcitonin Gene-Related Peptide
  • N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide
  • Calcium